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Abstract 
Introduction: Combination antiretroviral therapy (ART) has considerably reduced 
both the morbidity and mortality of Human Immunodeficiency Virus (HIV) infection 
and its associated complications, thus effectively transforming a fatal disease into a 
manageable chronic condition. However, the chronic use of ART has been 
accompanied by the emergence of adverse metabolic abnormalities in HIV-infected 
patients, including dysglycaemia. There is, however, a paucity of data from sub-
Saharan Africa on the incidence and risk factors associated with new onset diabetes 
mellitus in the HIV-infected population. Furthermore, efavirenz is the preferred 
nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line antiretroviral 
therapy (ART) regimens in low- and middle-income countries, where the prevalence 
of diabetes is increasing. Randomized control trials have shown mild increases in 
plasma glucose in participants in the efavirenz arms, but no association has been 
reported with overt diabetes. This study explores the risk factors and incidence of 
diabetes, and in particular the association between efavirenz exposure and diabetes, in 
a large Southern African cohort commencing NNRTI-based first-line ART. 
Subjects and Methods: The study cohort included HIV-infected adults commencing 
NNRTI-based ART in a private sector HIV disease management programme from 
January 2002 to December 2011. Incident diabetes was identified by the initiation of 
diabetes treatment. Patients with prevalent diabetes were excluded. The incidence of 
diabetes in patients receiving efavirenz versus nevirapine containing regimens was 
compared with a Kaplan-Meier plot and a log-rank test. The association of efavirenz 
exposure with the hazard of developing diabetes was modelled using a multivariate 
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Cox-proportional hazards model. The following variables were adjusted for in the 
regression model: age, sex, baseline BMI, baseline CD4, baseline viral load, exposure 
to diabetogenic drugs, and nucleoside reverse transcriptase inhibitor (NRTI) exposure. 
Results: Between January 2002 and June 2011, 62,467 patients commenced ART in 
the AfA program, of whom 56,298 patients met the inclusion and exclusion criteria 
and were included in the analysis. Median follow-up was 1.56 years (interquartile 
range (IQR): 0.71– 2.79 years), 21.7% of patients were followed up for 3 or more 
years. New onset diabetes was identified in 1500 (2.66%) patients over 113,297 
patient-years of follow-up (PYFU), giving a crude incidence of 13.24 cases per 1000 
PYFU. In the multivariate analysis treatment with efavirenz rather than nevirapine 
was associated with increased risk of developing diabetes (hazard ratio 1.27 (95% 
confidence interval: 1.10 - 1.46). Zidovudine and stavudine exposure, older baseline 
age, elevated baseline BMI, and exposure to diabetogenic medication were also 
associated with increased risk of diabetes. No association was found between baseline 
CD4 and an increased risk of diabetes. There was an association between the lowest 
stratum of baseline viral load and an increased relative risk for developing diabetes, 
but no association with higher viral load strata. 
Conclusion: Treatment with efavirenz, as well as stavudine and zidovudine, 
increased the risk of incident diabetes. Interventions to detect and prevent diabetes 
should be implemented in ART programmes, and use of antiretrovirals with lower 
risk of metabolic complications should be encouraged.  
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Chapter 1: Introduction 
Risk Factors for Incident Diabetes in a Cohort Taking First-Line 
Nonnucleoside Reverse Transcriptase Inhibitor-Based  
Antiretroviral Therapy 
1.1 Background 
Access to antiretroviral therapy (ART) in low- and middle-income country (LMIC) 
settings has considerably reduced both the morbidity and mortality associated with 
Human Immunodeficiency Virus (HIV) infection, thus transforming a fatal disease 
into a manageable chronic condition. However, the long-term use of ART has been 
accompanied by the emergence of adverse metabolic effects including insulin 
resistance and dysglycaemia, which are thought to be responsible for the association 
between long term ART and the risk of vascular disease.1,2 
In accordance with World Health Organization (WHO) guidelines, HIV infected 
patients in low-middle income countries (LMICs) requiring ART are initiated on a 
triple therapy regimen comprising two nucleoside reverse transcriptase inhibitors 
(NRTIs), and a non-nucleoside reverse transcriptase inhibitor (NNRTI) (either 
efavirenz or nevirapine).3 Protease inhibitors (PIs) (e.g. Lopinavir/ Ritonavir) were 
reserved as a second line therapy for adult patients experiencing treatment failure on 
first line agents. The decision of which specific NNRTI to use was determined largely 
by the respective side effect profile of the drugs. Efavirenz was thought to be 
teratogenic and therefore not advised for pregnant patients and its neuropsychiatric 
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adverse effects precluded its use in shift workers. Nevirapine demonstrated significant 
hepatotoxicity, dermatological adverse effects as well as Cytochrome P450 
interactions. The use of Nevirapine was therefore not advised in patients undergoing 
tuberculosis (TB) chemotherapy. Despite their adverse effects, the NNRTIs exhibited 
potent viral suppression. However, recent studies have linked the emergence of 
dysglycaemia, insulin resistance and new onset diabetes mellitus to efavirenz use in 
addition to the NRTIs and PIs.2,4
Within Sub-Saharan Africa (SSA), the burden of diabetes is growing and this is 
paralleled by an increasing prevalence of obesity which includes HIV-positive 
patients.5 Moreover, the impact of ART on the incidence of diabetes on a background 
of concomitantly increasing rates of obesity within SSA is undetermined. In addition, 
the recent trends of initiating ART at higher CD4 cell counts increases the lifetime 
exposure to these drugs thus making the likelihood of diabetes more incidental at 
younger age groups.3
At present, the added risk of diabetes mellitus (DM) in South African HIV patients on 
ART as compared to the general population is unknown. The findings from high 
income countries may not apply to the South African HIV infected population due to 
demographic and pharmacokinetic differences. The South African cohort of HIV 
infected patients comprises predominantly young black women as compared to 
middle-age men in developed countries.4 Furthermore, the ethnic variability with the 
SA HIV infected cohort, may impart a varied metabolic response to ART in these 
patients. The recent trend of initiating ART at higher CD4 cell counts means that 
there is increased overall exposure time to ART and possibly a greater lifetime risk of 
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developing DM as compared to the general population. Currently SA is experiencing 
an increasing incidence of diabetes especially in younger age groups.5,6 Risk factors 
include obesity, rapid urbanization, physical inactivity, nutrition transitions, and 
socioeconomic changes.5,6 It is unascertained how ART modifies the incidence of 
diabetes and the concomitant coronary heart disease (CHD) risk. First line ART 
regimens in developed countries utilise PIs whereas these agents are reserved as 
second line therapy in South African ART guidelines.3 It is also unknown whether the 
proposed metabolic abnormalities are dose dependant or develop due to increased 
time exposure.  
The paucity of data emanating from SSA makes it difficult to determine the additional 
risk of developing diabetes mellitus in HIV infected patients using ART. The aim of 
this study is to investigate the association between first-line ART use and the 
incidence of diabetes mellitus in a South African cohort of HIV infected patients, 
controlling for the effects of other drugs associated with developing diabetes mellitus.  
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1.2 Literature review 
1.2.1 Definition of Diabetes 
Diabetes mellitus is regarded as a state of hyperglycaemic decompensation that 
ensues when pancreatic β-cell secretion is insufficient to respond to bodily insulin 
requirements.  
Diabetes is defined as a fasting glucose >126 mg/dL (7.0 mmol/L), a plasma glucose 
level exceeding 200 mg/dL (11.1 mmol/L) 2 hours after a 75 g oral glucose load, or 
two random plasma glucose levels exceeding 200 mg/dL (11.1 mmol/L with 
symptoms of hyperglycaemia [thirst, polyuria, polydipsia, or recurrent infections]).7   
1.2.2 Diabetes Burden 
Diabetes affects about 336 million people worldwide.5 Distinct ethnic susceptibilities 
are evident, particularly where there have been rapid transitions from traditional 
lifestyles to affluent lifestyles characterized by sedentariness and consumption of high 
energy-density foods. About 7 million people develop diabetes each year; diabetes is 
expected to affect 438 million people by 2030.5 
According to the International Diabetes Federation, approximately 80% of people 
with diabetes live in low- and middle-income countries, where prevalence of diabetes 
is climbing.5,6,8  Within Sub-Saharan, which bears the brunt of the HIV epidemic, the 
estimated overall prevalence of diabetes in 2010 was approximately 1.42%, with 1.9 
million people living with the disease in South Africa alone.5 The escalating burden 
of diabetes is paralleled by increasing rates of obesity in LMICs, with recent estimates 
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suggesting that the number of obese adults in certain regions of sub-Saharan Africa 
already exceeding that of their western counterparts.8 Recent reports on the growing 
epidemic of obesity in HIV infected patients in LMICs are significant as obesity is an 
important risk factor for developing type II diabetes.9-11 The inherent increase in non-
communicable disease is expected to compound morbidity and mortality due to HIV 
associated infectious causes.12 Diabetes in HIV infected patients could therefore have 
a compound effect on the development of vascular disease, and opportunistic 
infections like tuberculosis.13,14 
1.2.3 Literature Search Strategy 
A systematic review of electronic literature was conducted in accordance with 
Cochrane Collaboration guidelines with the aim of investigating the association 
between ART use and disorders of glucose metabolism: insulin resistance and new 
onset diabetes mellitus. The literature search was initiated on 10/05/2010 and 
continued until 30/12/2016, however the literature cited in this study is not restricted 
to this timeframe.  
The search terms were; “anti-retroviral therapy AND diabetes OR dysglycaemia OR 
Insulin resistance,” “highly active anti-retroviral therapy AND diabetes,” “efavirenz 
AND diabetes,” “nevirapine AND diabetes,” “HIV AND diabetes,” “human immuno-
deficiency AND diabetes.”  
The following databases were searched for relevant articles; PubMed, EBSCO host, 
OVID, the Cochrane Controlled Trials Register in the Cochrane Library, 
ExcerptaMedica Database (EMBASE), and a clinical trials web site 
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(ClinicalTrials.gov). Included were articles in any language published from the 
beginning of each database until December 2016. For all included articles, a lateral 
search in PubMed by using the “related articles” link was performed.  
No filter was employed to limit the search to developing country (resource-limited) 
settings. Randomised controlled trials, cohort and cross sectional studies that had been 
conducted in countries with a low or middle level of human development were 
included. Potentially relevant studies were included by reviewing titles and abstracts 
retrieved from bibliographic databases. Studies identified as potentially relevant were 
retrieved in full text and screened for inclusion. Of the eleven abstracts retrieved from 
the Pubmed search, only two were relevant to this study and were therefore included 
in the present review. Similarly, only 78 of the 114 papers retrieved from the 
literature search were relevant to this study and were therefore included in the present 
review.   
1.2.4 Diabetes-conventional Risk Factors 
1.2.4.1 Age 
In the HIV seronegative population, age is a significant factor predisposing to the 
development of insulin resistance and type II diabetes mellitus.12
The Swiss HIV Cohort Study (SHCS), a prospective observational cohort, studied the 
influence of aging on the epidemiology of non-AIDS diseases in an HIV infected 
cohort categorized into 3 age groups: <50, 50–64, and >65 years of age. Seventy 
cases of diabetes were reported in the cohort of 8848 patients. The age stratified 
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incidence of diabetes was 2.09 per 1,000 person-years, 4.65 per 1,000 person-years 
and 8.56 per 1,000 person-years in the age groups <50, 50–64, and >65, respectively, 
suggesting that incidence of diabetes increases with advancing age.15 The prospective 
collection of adverse events and the statistical power were significant strengths of the 
SHCS. The study was however limited by lack of a demographically comparable 
HIV-uninfected control group. The latter obscures the interpretation of advanced age 
and the incidence of diabetes, as the increased comorbidity of diabetes may be due 
solely to aging or due to attenuated immune recovery in elderly HIV infected 
patients.15  The findings of the SHCS were however corroborated by Capeau et al, 
2012, in the ANRS CO8 APROCO-COPILOTE Cohort Study.16 This prospective 
study with a cohort of 1046 patients representing 7,846 PYFU evaluated the incidence 
of diabetes in combination ART treated individuals. A total of 111 
patients developed diabetes, with an incidence of 14.1/1,000 PYFU. The investigators 
reported that the incidence of diabetes was associated with older age, specifically, an 
adjusted hazard ratio of 2.13 and 3.63 for the groups aged 40-49 years, and ≥50 years 
respectively.16 Unlike the SHCS, the ANRS CO8 APROCO-COPILOTE Cohort 
Study was limited in power due to the number of patients included in the study. 
Furthermore, the ANRS CO8 APROCO-COPILOTE Cohort Study was initiated in 
1997-1999, where the use of older antiretrovirals (stavudine and indinavir) now 
known to be strongly associated with the development of diabetes was commonly 
used.2 The subsequent availability of less toxic antiretrovirals and drug policy 
changes resulted in a lower incidence rate of diabetes in follow up years. The effect of 
calendar year/date of inclusion was not observed in the SHCS.  Despite the limitations 
noted, the ANRS CO8 APROCO-COPILOTE Cohort Study noted a significant 
association between short-term exposure to indinavir, stavudine and didanosine and 
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diabetes, which was not observed in patients exposed for a longer term to these 
drugs.16 The relationship between age and the incidence of diabetes in HIV treated 
patients may not be a simple linear association. The findings of the SHCS and the 
ANRS CO8 APROCO-COPILOTE Cohort Study suggest that patients who are 
genetically predisposed to diabetes, develop the disease in the initial years of 
antiretroviral therapy whereas patients not prone to diabetes may tolerate long term 
ART without developing disorders of glucose metabolism.16 
1.2.4.2 Sex 
The current literature reflecting metabolic aberrations in HIV seropositive patients 
contain a predominance of male subjects. Despite this, most contemporary studies 
indicate that male sex poses a greater risk for the development of insulin resistance 
and overt diabetes.4 There is however, in-homogeneity in the rates, risks and 
prevalence of gender associated diabetes reported in the studies published to date. The 
results of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study2, a 
large, prospective observational study, indicated that relative risk of diabetes was 60% 
greater for the male sex, whilst the French 10 year study by Capeau et al, 2012, 
reported incidence rates of 14.6/1,000 PYFU and 12.6/1,000 PFYU in men and 
women respectively.16 The strength of the D:A:D study is the large number of study 
participants (over 22,000 patients) collated from 11 separate cohorts. However, as a 
limitation, the fragmented nature of the cohorts did not enable the investigators to 
fully evaluate the effects of treatment interruption and adherence.2  
The prospective Women’s Interagency HIV study investigated the incidence of 
diabetes in a cohort comprising 1,524 HIV infected and 564 HIV uninfected 
individuals.17 In this cohort, diabetes developed in 116 HIV infected patients and 36 
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HIV uninfected women over 6,802 PYFU. The incidence rate of diabetes in the ART 
naïve group was 1.53/100 person-years as compared to an incidence rate of 2.50/100 
person-years and 2.89/100 person-years in patients receiving PI-based and non-PI-
based ART regimens, respectively.17 These rates were however, paralleled by an 
incidence rate of 1.96/100 person-years in a group of HIV uninfected women in  a 
study by Justman et al, 2003.18 In the latter study, the HIV-seronegative group had 
higher BMIs than their sero-positive counterparts (33% versus 23%), however 
counter-intuitively, displayed half the rate of new onset diabetes.18 The suggestion is 
that female ART-exposed patients have a greater likelihood of developing diabetes at 
relatively lower BMIs and adiposity levels. The literature to date indicates that ART 
exposed men have a greater risk of developing diabetes compared to women. 
However, women may develop dysglycaemia at lower adiposity levels.15,19 This 
gender difference may reflect the variation in drug metabolism, with women 
inherently having lower rates of hepatic drug elimination.16 
1.2.4.3 Central Obesity and Omental Adipose Tissue Accumulation 
It is well established that obesity and visceral fat accumulation are integral to the 
pathogenesis of insulin resistance and the subsequent progression to diabetes 
mellitus.20,21 The clinical measurement of waist to hip ratio has proven to be a better 
surrogate marker in the determination of the risk of developing diabetes. Elevated 
waist to hip ratios, rather than overall BMI, reflect on the type of adipose tissue 
distribution that subtends a greater risk of developing diabetes. This body habitus is 
similar to that of patients suffering from lipodystrophy/ lipoatrophy syndromes as a 
consequence of long term ART exposure.15, 16 
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The return to health, reconstitution of the immune system, and rapid weight gain 
observed in patients initiated on ART may compound the risk of developing diabetes 
inherent to HIV chemotherapy. The D:A:D study reported a fourfold increase in the 
rates of new onset diabetes in clinically obese patients as compared to controls with 
healthy BMIs.2 Capeau et al, 2012, reported new onset diabetes hazard ratios of 1.91 
and 2.85 for overweight and obese patients respectively, in 10-year follow-up 
period.16   
 
1.2.4.4 Lipid Disturbances and the Metabolic Syndrome 
The metabolic aberrations in diabetes are characterised by elevated plasma levels of 
triglycerides and lowered levels of high-density lipoprotein (HDL).21 These, in 
combination with increased central visceral adiposity, inherent insulin resistance and 
elevated blood pressure are significant components of the metabolic syndrome. The 
D:A:D study investigated the characteristics of lipid dysregulation in HIV- 
seropositive patients and reported elevated triglycerides levels and lowered HDL 
levels, both of which were component predictors of new onset diabetes mellitus.2 
Specifically, triglyceride levels two times higher than normal translated into an 80% 
increased risk of developing diabetes, whereas higher HDL levels impart a protective 
effect against dysglycaemia. Elevated total cholesterol paralleled the predictive effect 
of elevated triglycerides. In this instance, lipid aberrations serve as a proxy marker in 
predicting the risk of developing diabetes.2 An international cross sectional study by 
Samaras et al, 2007, reported that the prevalence of diabetes is approximately five to 
nine times higher in HIV seropositive individuals co-afflicted with the metabolic 
syndrome.20 It is pertinent to note that this cohort emanated from large tertiary referral 
centres in high-income settings, and the results may not be generalizable to LMICs 
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such as SSA with lower levels of education, socio-economic status and suboptimal 
nutrition. 
Results from the INITIO trial, an international, multicentre, randomized clinical trial 
suggests that patients with already present metabolic syndrome at the start of ART 
had a four times greater risk of developing diabetes.22 The INITIO trial investigated 
the effect of three ART initiation strategies and the incidence of metabolic syndrome, 
cardiovascular disease and type 2 diabetes mellitus in treatment-naive HIV infected 
participants. The INITIO trial indicated that the onset of metabolic syndrome whilst 
on ART is associated with a higher risk of incident diabetes.22 These findings reaffirm 
the contributory factors that lipid aberrations impart to the risk of developing diabetes 
mellitus. The study was however limited as there was departure from protocol-
specified initial ART regimens. Most participants received didanosine and stavudine, 
agents that are strongly associated with diabetes and are no longer recommended as 
first line therapy, which may have also masked the effects of other drugs such as 
efavirenz and the development of metabolic syndrome.  
 
1.2.4.5 Hepatitis C Co-infection 
Chronic hepatitis C infection has a well-established association with development of 
peripheral insulin resistance.23 The risk of subsequent diabetes development is 
debated. Retrospective studies have reported a diabetes prevalence twice as high in 
hepatitis C co-infected HIV positive patients, whereas other studies have reported no 
association.16,24 The prevalence of hepatitis C is low in South Africa and is therefore a 
less significant factor in the development of insulin resistance.  
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1.2.4.6 Direct Viral Effects 
Prior studies suggest that patients with untreated HIV infection have increased 
dyslipidaemia and elevated levels of bio-inflammatory markers predisposing to the 
development of insulin resistance.25,26 
1.2.4.7 Duration of HIV Infection 
There is a paucity of data reflecting the relationship between duration of HIV 
infection and the development of diabetes mellitus. Recent studies however, have 
suggested that there is no association between length of HIV infection and 
dysglycaemia.16  
1.2.4.8 CD4 Nadir 
There appears to be conflicting results with respect to nadir CD4 count and the 
development of insulin resistance. The Multicenter Aids Cohort Study (MACS) found 
that CD4 nadir less than 300 cells/mm3 was associated with increased risk of insulin 
resistance, whereas the ANRS CO8 APROCO-COPILOTE cohort found no 
difference in the incidence of diabetes with nadir CD4 less than 200 cells/mm3
compared to CD4 counts greater than 200 cells/mm3.16,19
1.2.4.9 Body Fat Redistribution disorders 
NRTIs and PIs have demonstrated variable effects on mitochondrial toxicity in 
muscle and adipose tissue.27,28 More specifically there is a decrease in subcutaneous 
adipose tissue, increased visceral adipose tissue deposition and altered lipid 
metabolism (Refer to Figure 1). Lipodystrophy, the term that encompasses the 
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clinical manifestations of altered lipid and adipose tissue redistribution, appears to 
exacerbate insulin resistance.29,30
1.2.4.10 Diabetes Prevalence and Incidence in HIV Infected Patients 
The occurrence of diabetes in HIV infected patients was relatively uncommon, with 
early studies indicating an incident rate of 2.0 – 2.6% in ART naïve patients.31,32 The 
introduction of combination ART and the widespread use of PIs in particular have 
heralded a rapid increase in the incidence of new onset diabetes mellitus.21,33,34 It was 
subsequently established that patients on ART had a higher predilection/propensity to 
develop glucose intolerance and overt DM than their counterpart controls.20,35,36 The 
reports of incident diabetes vary widely due to the differential initiation of ART drugs 
i.e. PI based therapy versus NNRTI based therapy in accordance with differeing 
health policies. Eliciting the true prevalence and incidence of diabetes in context of 
HIV infected populations is complicated by confounding variables such as genetic 
differences in study populations and the differences and in-homogeneity in diagnostic 
and statistical methods used by investigators.   
As part of the metabolic syndrome, hyperinsulinaemia is often accompanied by 
truncal adiposity, increased waist-to-hip ratios, ‘buffalo hump’ and loss of limb fat. In 
a small prospective cohort study, Hadigan et al, 2001, reported that in such patients 
there was a DM incidence of 7% compared with 0.5% in healthy controls.37    
Cross sectional studies by Carr et al, 1998-1999, investigated ART associated 
lipodystrophy and found a 2% incidence of diabetes, which subsequently rose to 7% 
after a 14 month observation period and an overall 25% prevalence of all glucose 
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disorders.29,30 Importantly, these studies were limited to the protease inhibitor class of 
drugs. Calza et al, 2011 have reported prevalence rates of diabetes and impaired 
fasting glucose rates of 4.5% and 9.1% respectively in a prospective cohort study 
including 755 HIV patients.36 This study was limited by the number of patients 
enrolled, but did find significant associations between new onset diabetes and the 
NRTIs; stauvdine, didanosine and zidovudine.38 Studies with a longer period of 
follow-up have demonstrated a fourfold increase in the relative risk of developing 
new onset diabetes (10% of ART patients over a four year follow-up period as 
compared to 3% in HIV-seronegative controls).19 The D:A:D study reported a 
diabetes incidence rate of 5.72 per 1,000 person-years of follow-up (PFYU) having 
observed 33,389 HIV seropositive patients for an average of 3.8 years.2 Conclusions 
from the D:A:D study suggest that new onset diabetes was strongly associated with 
use of the NRTI stavudine, and that exposure to the NRTIs; zidovudine and 
didanosine also impart an increased risk of developing diabetes, after controlling for 
potential diabetogenic risk factors.2 In contrast, the PI, ritonavir, and the NNRTI, 
nevirapine, were associated with reduced risk of diabetes.2 
The findings from the D:A:D study were corroborated by the Swiss HIV Cohort 
Study which reported an incidence of 3.12 cases per 1,000 PFYU.15 Over a 3 year 
observation period of 8,444 participants, the prevalence of diabetes had increased 
from a baseline of 4% to 7%.15 The prospective Multicenter Aids Cohort Study 
(MACS) reported the incidence of DM in a cohort of 411 HIV-infected men with 
HAART exposure was greater than 4 times that of HIV-seronegative men.19 The rate 
of incident DM in the MACS was 4.7 cases per 100 person-years among HIV-
infected men using ART compared with 1.4 cases per 100 person-years among HIV-
seronegative men, after adjustment for age and body mass index in a 4 year 
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observation period.19 This represented a 14% incidence of diabetes in HIV-infected 
men exposed to ART in comparison to HIV-seronegative controls.19 The MACS trial, 
however, had several limitations; the end point determination of diabetes mellitus was 
based on a single fasting blood glucose level measurement, self-reported diagnosis of 
diabetes, not investigating the effect of hepatitis C on incident diabetes, and selection 
biases.  
Capeau et al, 2012, investigated the ten-year diabetes incidence in 1,046 HIV-infected 
patients started on a combination antiretroviral treatment.16 In this study cohort with 
7,846 person-years of follow-up (PYFU), 111 patients developed diabetes, with an 
incidence of 14.1/1,000 PYFU. The incidence of diabetes was associated with older 
age, elevated body mass index, waist-to-hip ratio and exposure to indinavir, stavudine 
and didanosine.16 
Polsky et al, 2011, studied the incidence of hyperglycaemia among older adults with 
or at risk for HIV infection.39 In a prospective cohort comprising 377 participants 
followed up over an 18-month period with baseline rates of diabetes of 7% and pre-
diabetes of 31%, the incidence of new onset diabetes was found to be 5%. 
Importantly, the authors concluded that neither HIV infection nor ART use were 
associated with increased risks of diabetes.39 The strength of the study was endpoint 
determination by use of oral glucose tolerance tests, but was limited by the lack of 
confirmatory testing. This study was also limited by the small number of incident 
cases, which diminished the ability to detect associations between certain risk factors, 
and incident diabetes as described above.  
The Women’s Interagency HIV Study likewise investigated the incidence of diabetes 
mellitus in a cohort of HIV infected women (1,524 HIV infected subjects) as 
compared to a control group (564 HIV uninfected subjects).40 ART-naïve HIV 
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infected patients had a DM incidence rate of 1.53/100 person-years; those reporting 
ART containing a protease inhibitor (PI) had a rate of 2.50/100 person-years and 
those reporting non-PI-containing ART regimen, a rate of 2.89/100 person-years. The 
HIV-uninfected control group had an incidence of 1.96/100 person-years.40 The lower 
DM incident rate observed in the WIHS trial is less than that observed in the MACS 
trial, which may be indicative of a less sensitive case detection method.19,40  
 
1.2.5 Diabetes and HIV in Africa 
There are several small studies emanating from Sub-Saharan Africa providing age 
adjusted prevalence estimates for diabetes among the HIV infected population.  
Dave et al, 2011, reported on South African cross sectional data where the prevalence 
of dysglycaemia in 406 ART-naïve patients and 443 patients on ART were 25.7% and 
21.9% (P = 0.193), respectively.4 However, there were higher levels of impaired 
fasting glucose (IFG) in the ART treated group (23.5%) as compared to the ART 
naïve group (18.5%).4 The study was limited by the lack of an HIV negative control 
group, a short duration of ART exposure, and a relatively small number of male 
patients.  The prevalence of impaired fasting glucose was 16-18% in a Rwandan cross 
sectional study of 571 patients receiving ART for more than 6 months.41 Manuthu et 
al, 2008, reported a diabetes prevalence and IFG of 1.5% and 21.4%, respectively, in 
a Kenyan cross sectional study of 295 patients receiving ART for more than a year.42 
Zannou et al, 2009, reported a diabetes prevalence and IFG of 1.5% and 34-37%, 
respectively, in a prospective Benin cohort in 79 patients receiving ART for more 
than a year.43 Most of the literature to date investigating HIV, ART and diabetes is 
limited by a lack of internal controls prohibiting the estimation of relative risk.  
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1.2.6 Pathogenesis of ART Related Insulin Resistance and Diabetes Mellitus 
Whilst it is suggested that ART may influence the development of insulin resistance2, 
the established traditional risk factors such as family history, elevated body mass 
index, smoking, and advanced age may be more significant factors in the 
pathogenesis of overt diabetes mellitus. 
 
In summary, the proposed mechanisms that lead to the development of insulin 
resistance and diabetes in the context of HIV infection are attributed to either one or a 
combination of the following factors:44,45 
• Antiretroviral agents 
• Co-morbidities, such as chronic hepatitis C infection 
• Opportunistic infections 
• Altered fat distribution: visceral fat accumulation/ subcutaneous lipoatrophy 
• Mitochondrial dysfunction 
• Elevated circulating free fatty acids 
• Increased muscle and organ fat 
• Elevated pro-inflammatory cytokine release 
• HIV direct viral effect 
• Diet and lifestyle 
• Genetic predisposition 
 
1.2.7 Drug Exposures 
Studies in resource-rich settings have shown an association between long-term ART 
and the risk of vascular disease, which is postulated to be due to adverse metabolic 
effects of antiretroviral drugs.1 Dysglycaemia, insulin resistance, and diabetes mellitus 
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have been linked to a variety of antiretroviral drugs from three different classes: the 
nucleoside reverse transcriptase inhibitors (NRTIs), stavudine and zidovudine, the 
protease inhibitors (PIs), indinavir and ritonavir, and more recently, the non-
nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz.4,46,47 
 
1.2.8 Antiretroviral Effects 
Early reports and cases indicated that disorders of glucose and lipid metabolism were 
primarily due to PI therapy.33 However, Brinkman et al, 1999, reported on data which 
suggested that NRTIs may be contributing factors in the pathogenesis of ART-
associated insulin resistance and diabetes.48 The pathogenic mechanism elucidated 
suggests that whilst NRTIs are potent inhibitors of HIV reverse transcriptase, the 
drugs also inhibit an integral mammalian enzyme, DNA polymerase-γ, responsible for 
mitochondrial replication.48 The dysregulation of mitochondrial function in different 
compartments of the body results in various clinical manifestations of NRTI toxicity. 
The inhibition of mitochondrial replication in muscle manifests as insulin resistance, 
whereas mitochondrial dysregulation in the liver increases the propensity to develop 
lactic acidosis. Dysfunctional mitochondria in adipose tissue predispose to the 
development of lipoatrophy, and peripheral neuropathy results from dysfunctional 
neuronal mitochondria. Brown et al, 2005, found that exposure to NRTIs most 
strongly correlated with insulin resistance after controlling for other risk factors; age, 
BMI, and CD4 count.35 The D:A:D study also found that cumulative exposure to 
NRTIs increased the risk of insulin resistance, with the highest risk attributed to 
stavudine followed by zidovudine, and lamivudine.2 Studies indicate that HIV 
infection itself as well as ART may be responsible for altered pancreatic β-cell 
responses to plasma glucose, and hence inadequate insulin secretion.49-51  
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1.2.9 Insulin Resistance Associated with Protease Inhibitor Use 
Within the PI class, insulin resistance has been most commonly observed with  
ritonavir, indinavir and nelfinavir.52 Ritonavir has been reported to impair beta cell 
function with a concomitant reduction of insulin synthesis of between 25 to 30%.53  
Noor et al, 2004, demonstrated that insulin resistance was induced in healthy subjects 
after administration of lopinavir/ritonavir for 5-10 days of treatment.54 Indinavir, and 
lopinavir/ritonavir to a lesser extent, inhibits the rate-limiting step in glucose uptake 
into muscle and adipose tissue; i.e. insulin stimulated glucose transport mediated by 
Glucose Transporter Type 4 (GLUT4).46 Other proposed mechanisms by which PIs 
lead to insulin resistance include inhibition of peroxisome proliferator-activated 
receptor gamma (PPAR-γ) and sterol regulatory element-binding protein (SREBP). 
PPAR-γ is involved in insulin resistance by regulating the maturation and metabolic 
activity of adipocytes. The products of adipocyte metabolism include adipokines, 
such as adiponectin and leptin, which mediate the activity of insulin in peripheral 
tissues.52 Other studies suggest that insulin resistance, and overt diabetes associated 
with PIs may be a result of immune reconstitution, a subsequent increase in body 
mass index55, and induction of lipodystrophy and dyslipidaemia.56 
1.2.10 Insulin Resistance Associated with NNRTI Use 
There are limited studies investigating the effects of NNRTIs, and the development of 
insulin resistance and diabetes. The available data has indicated that nevirapine-based 
ART may be protective against insulin resistance relative to efavirenz-based therapy, 
and that efavirenz may be associated with overt dysglycaemia.4,47  
A prior cross sectional study found an increased risk of dysglycaemia in South 
African patients taking efavirenz compared with those taking nevirapine, but there 
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were insufficient numbers of cases of diabetes for analysis.4 A small case–control 
study from Botswana suggested an association between efavirenz use and diabetes.57 
Randomized controlled trials showed significantly higher serum glucose 
concentrations in participants in the efavirenz arms than the following comparator 
antiretroviral drugs: nevirapine,58 abacavir,58 atazanavir,59 atazanavir–ritonavir,60  and   
raltegravir.61 
The mechanism by which efavirenz mediates insulin resistance and diabetes is 
unknown. Possible mechanisms include mitochondrial toxicity62, and toxic effects on 
adipocytes and increased rates of lipoatrophy.63,64 Efavirenz causes hepatic 
mitochondrial toxicity62, and induces hepatocyte endoplasmic reticulum stress leading 
to activation of the unfolded protein response, and apoptosis.39,40 Efavirenz mediates 
mitochondrial toxicity via various mechanisms. Firstly, efavirenz directly inhibits 
Complex I of the electron transport chain, resulting in a markedly reduced 
mitochondrial transmembrane potential, thus compromising oxidative 
phosphorylation and ATP generation.65-67 Secondly, efavirenz reduces complex IV 
(COIV) mRNA (a marker gene of mitochondrial function), and impairs mitochondrial 
function in adipocytes.68 Furthermore, efavirenz associated mitochondrial 
dysregulation in adipose tissue causes impaired adipogenesis, increased lipolysis, and 
release of free fatty acids and inflammatory cytokines.68 The increased release of fatty 
acids due to adipocyte mitochondrial toxicity are thought to impair muscle and liver 
insulin sensitivity, leading to insulin resistance and diabetes mellitus.45,69-74 In 
addition to its mitochondrial toxicity, efavirenz has been shown to reduce the 
secretion of adiponectin (an insulin-sensitizing, anti-diabetic adipokine) by 
adipocytes.68 It is therefore hypothesized that impairment of mitochondrial 
bioenergetics and toxicity to adipocytes contributes to the development of diabetes in 
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patients on efavirenz. By contrast, nevirapine does not appear to exert mitochondrial 
toxicity.63,68 
Prior studies have demonstrated a positive correlation between plasma efavirenz 
concentrations, and both fasting and 2-hour glucose concentrations after oral glucose 
tolerance tests in South African patients.75 People of African origin are more likely to 
be genotypic “slow metabolizers” of efavirenz, which results in elevated efavirenz 
plasma concentrations, than people of European descent (20% and 3%, 
respectively).76 Therefore efavirenz may have a larger diabetogenic effect in Africans, 
which may explain why studies from high-income countries have not found an 
association between efavirenz and diabetes. 
 
1.2.11 Non-Antiretroviral Effects: Epidemiological Evidence and Mechanisms 
In essence, it is difficult to delineate the metabolic effects of ART from those of HIV. 
There are few studies that describe the prevalence of diabetes in ART-naïve HIV 
infected patients. El Sadr et al, 2005, investigated the effects of HIV infection on 
lipid, glucose and insulin levels in 419 ART-naïve patients and found a 2.6% baseline 
prevalence of diabetes in their cohort.31 
 
Immunological studies have indicated that HIV infection is associated with elevated 
plasma levels of tumour necrosis factor (TNFα) and other cytokines that may alter 
glucose metabolism.77 Certain HIV expressed proteins (Tat and Vpr) have a 
propensity to directly induce the development of insulin resistance. In particular, Vpr 
inhibits PPAR-γ activity and dysregulates the transcriptional activity of insulin.78 Tat 
activates Nuclear Factor-kappa B, which in turn increases TNFα secretion. There is 
subsequent decreased uptake of free fatty acids by adipocytes, suppression of insulin 
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receptor and insulin signalling events, and decreased GLUT4 translocation and 
phosphorylation of the insulin receptor substate-1 (IRS-1).79-81 Immune reconstitution 
following ART initiation may result in an increased and paradoxical inflammatory 
response, thus promoting insulin resistance. Brown et al, 2010, reported that the 
initiation of ART was followed by elevated TNFα levels at 48 weeks with associated 
incident diabetes mellitus.82  
 
1.2.12 Prevalence of the Metabolic Syndrome 
Hyper-insulinaemia and impaired glucose tolerance are components of the metabolic 
syndrome. It is therefore imperative to assess HIV infected individuals, whether 
treated or not, for development of the metabolic syndrome, as each individual 
component precludes the development of another.  
Estrada et al, 2006, studied the prevalence of lipodystrophy and the metabolic 
syndrome in HIV-infected patients on ART and concluded that the prevalence in the 
ART group was 15.8% as compared to 3.2% in the HIV seronegative healthy 
controls.36 This study was limited by a lack of fat distribution measurements for the 
entire study population and in general, a lack of an objective criterion of the diagnosis 
of lipodystrophy.  In the Women’s Interagency Study, the HIV-seropositive group had 
a 33% prevalence of the metabolic syndrome whilst the HIV-seronegative controls 
had a prevalence of 22%.40 
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Figure 1. The potential pathways and mechanisms of ART induced insulin resistance 
and diabetes (ART; Antiretroviral Therapy).42,44,46 
 
 
1.2.13 Separating the Effects (Drugs versus Virus) 
Studies have suggested that untreated HIV infection and high viraemia levels are 
independent risk factors for endothelial damage.83 The subsequent inflammation is 
linked to accelerated atherosclerosis and the inherent risk of cardio/cerebrovascular 
ischaemic events.83 The viraemia associated inflammatory response may also be 
related to pancreatic β-cell dysfunction, which upon a background of elevated BMI, 
traditional risk factors and lipodystrophy may lead to insulin resistance and overt 
diabetes mellitus.83 The dilemma in evaluating and analysing treated HIV seropositive 
patients is the inability to separate the effects of high viral loads, and ART. It is 
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therefore uncertain whether disorders of glucose metabolism and vascular disease are 
due to untreated viraemia, ART or a combination of both.44 What is known is that 
ART rapidly lowers viral loads with a concomitant rise in CD4 cells. The 
development of insulin resistance and diabetes may then be more likely due to ART 
effects, a rapid return to health and increasing BMI upon a background of traditional 
diabetes risk factors and advancing age.40 
 
Furthermore, the effects of ART and the development of immune reconstitution 
inflammatory syndrome (IRIS) soon after the initiation of therapy are well 
established.84 It is plausible that the generalised inflammatory state may contribute to 
the pathogenesis of insulin resistance and diabetes early on in therapy. The observed 
metabolic complications observed in HIV treated patients may, however, be due to 
either toxic effects of long term ART, chronic inflammation associated with HIV 
infection, lifestyle related factors and advancing age.15  
Current literature poorly reflects the influence of HIV infection and ART on a 
population with a background of age-related β-cell dysfunction. It is uncertain 
whether HIV and ART exacerbate the genetic susceptibility in the general population, 
making family history a pertinent clinical consideration/factor, or by directly 
impacting on the pathogenesis of insulin resistance and diabetes.  
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1.2.14 Diabetic and Vascular Complications in HIV 
 
 
1.2.15 Consequences of Diabetes Mellitus 
The long-term consequences of diabetes mellitus have implications for multi-organ 
disease and can be attributed to both micro and macro-vascular complications. 
Several pathologies become manifest and significant morbidity and mortality is 
attributed to the development of diabetic retinopathy and nephropathy.  In the context 
of cardiovascular disease, there have been reports of myocardial infarctions and 
related mortality in the younger HIV seropositive patients on ART.85 This link is 
important as diabetes is considered a coronary heart disease equivalent in the general 
population. It is undetermined whether the development of insulin resistance and 
subsequent diabetes mellitus is accelerated by concurrent HIV infection. The D:A:D 
study reported a myocardial infarction incidence of 7.6% in patients with pre-existing 
diabetes but without pre-existing coronary heart disease, and 31.1% for those with 
pre-existing coronary heart disease without concurrent diabetes.86 The suggestion is 
Figure 2. Schematic diagram depicting the possible implications and consequences of 
long-term ART.1,2, 121 
35 
that within this cohort, diabetes is not a coronary heart disease equivalent in HIV 
seropositive patients, despite the fact that diabetes remains a significant risk factor for 
the development of CHD.  
1.2.16 Risk Profiling 
The clinical relevance of the emergent cohort data suggesting an association between 
ART use and diabetes has enabled the development of population specific risk 
profiles that aid in predicting the short-term risk of diabetes in HIV-positive 
patients.87 Several models that predict the risk of diabetes in the HIV seronegative 
population have been described.88-91 Commonly included variables include age, sex, 
weight, glucose, blood pressure, HDL-C, triglyceride and family history of diabetes. 
Whilst these models have been proven to be adequate predictors of diabetes in the 
HIV seronegative population, their utility has not been validated in HIV infected 
patients, and in particular those patients within the SSA region.   
The D:A:D study group developed and compared a predictive model to the well-
reported Framingham equation.91 The investigators found that the factors most likely 
to predict diabetes included elevated blood glucose levels, higher BMI, elevated 
triglyceride levels and older age.87 Factors predictive of diabetes within the HIV 
context included recent CD4 counts <200 cells/µL and lipodystrophy. The authors 
concluded that the Framingham equation over-estimated the likelihood of diabetic 
incident events in comparison to the D:A:D equation with reference to the parameters 
of blood glucose levels, triglycerides and BMI levels below 25kg/m2.87
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1.2.17 Non-communicable Disease Patterns in Sub-Saharan Africa 
The prevalence of diabetes within SSA is determined by several dynamics; 
demographic changes, ageing populations, urbanization, and an increasing burden of 
obesity and physical inactivity.92 
 
Hall et al, 2011, reported that type II diabetes mellitus accounts for more than 90% of 
the diabetes burden in SSA.93 The population prevalence proportions ranged from 1% 
in rural Uganda to 12% in urban Kenya.93 The proportion of diabetic patients 
suffering diabetic complications ranged from 7-63% for retinopathy, 27-66% for 
neuropathy, and 10-83% for microalbuminuria.93 The prevalence of diabetes 
associated coronary heart disease ranges from 4% to 23% for the black and white 
population, respectively, in a South African study.94 Diabetes induced immuno-
suppression is also likely to increase the risk of mortality from several infections 
including; tuberculosis, pneumonia and sepsis. The prevalence of obesity and insulin 
resistance within the SSA region is also influenced by the use of ART. Within the 
SSA region, the five-year mortality proportions of patients with diabetes ranges from 
4 – 57%.93 
 
South Africa has a large and growing burden of non-communicable diseases, 
especially diabetes, obesity, hypertension and cardiovascular disease.95,96 The World 
Health Organization (WHO) estimated that in 2004, 28% of the total burden of 
disease in South Africa was attributable to non-communicable disease.97 South 
Africans of lower socioeconomic status residing in urban environments are worst 
affected and have increased demands for chronic disease care. 98,99 
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The relationship between diabetes and cardiovascular disease is inextricable, and in 
the current South African context, cardiovascular morbidity is still characterised by 
the persistence of rheumatic heart disease, idiopathic cardiomyopathies, and 
hypertensive disease.96 There is, however, an emergence of obesity and diabetes and a 
likely concomitant increase in ischaemic heart disease (IHD) incidence in South 
African rural communities.96,100  
There are several gaps in knowledge regarding diabetes and HIV infected patients in 
SSA. It is unknown whether there is an increase in new onset diabetes mellitus 
disease among HIV infected South African patients as compared to the uninfected 
population with similar characteristics. It is unknown if the incidence of diabetes 
mellitus increased in HIV infected South African patients on ART. Furthermore, do 
the NRTIs, NNRTIs and PIs exert a class effect risk of diabetes, or are there specific 
drugs associated with increased risk of diabetes? There is no data on the 
characteristics of HIV infected patients in the South African population who are at 
greatest risk for diabetes. This study aims to address some of these questions.  
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1.3 Aims and Objectives 
1.3.1 Objectives 
To investigate the association between ART exposure and the incidence of new onset 
diabetes mellitus in a cohort Southern African HIV infected adults. 
1.3.2 Specific aims 
In South African HIV infected adults: 
1. To assess the incidence of diabetes mellitus in patients on ART (as per
initiation of anti-hypoglycaemic agents and statin therapy), and to determine if
there is a duration-dependent increase in risk associated with exposure to
ART, or any ARV drug class;
2. To determine the risk factors associated with new onset diabetes mellitus in
patients on ART.
39 
Chapter 2: Methodology
2.1 Methods 
2.1.1 Study design 
Retrospective cohort study. 
2.1.2 Study Population and Data Source 
The study population comprises South African HIV infected adults enrolled in a 
private sector HIV disease management program, Aid for Aids (AfA), a company that 
was contracted to oversee the HIV-related care in members from a number of private 
medical insurance schemes in Southern Africa. HIV-related care was undertaken by 
private care physician or general practitioner registered with AfA, and members were 
accepted into the program if the diagnosis of HIV infection was confirmed, or they 
had been exposed to HIV, and require post exposure prophylaxis. AfA has been 
operating since June 1998, and maintained a database with information captured on 
registration, and on an ongoing basis as part of their founding directive. The AfA 
program collects demographic, laboratory, and clinical data on individuals who 
registered for HIV benefits. Claim data were captured by AfA from the medical 
insurance fund claim database. These include laboratory, hospitalization, pharmacy, 
and medical practitioner claims which were submitted to the scheme for processing 
either: at the time of the service by the provider (e.g. pharmacy, hospitalization) for 
direct reimbursement, or after the service date by the member where the member had 
already paid the claim. Reimbursement was subject to established AfA protocols, 
including protocols for ART initiation, change of ART regimen, and the treatment of 
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certain opportunistic infections. No co-payment was required for ART, viral load 
(VL) and CD4 monitoring, and doctor visits. 
Despite being a private sector program, AfA standardized guidelines for HIV 
management, are similar to the WHO guidelines for LMICs.101 Patients were eligible 
for ART initiation if their CD4 cell count was below 350 cells/mm3, or they had 
WHO stage 3 or 4 illness irrespective of the CD4 count. The recommended initial 
regimen was a combination of 2 NRTIs and an NNRTI. VL and CD4 counts were 
monitored every 6 months. 
Data linkage to the South Africa death registry allowed ascertainment of deaths and 
date of death,.102,103 Civil identification numbers, Republic of South Africa Identity 
(RSAID) number, were cross-checked in the national death registry to confirm or
ascertain dates of death for those with registered deaths. All data were de-identified 
prior to analysis. Linkage to the death registry was essential in performing a 
competing risk analysis. 
2.1.3 Data collation 
Data was pooled from separate medical aid schemes (Medscheme, Bonitas and 
GEMS) and collated using Microsoft SQL Server® 2008 (Fig. 3, pg. 41).  Patients 
were identified by RSAID numbers and then assigned an internal cohort identifier. 
Patients were matched across schemes via use of a protocol that detailed their each 
unique RSAID numbers, name, surname, date of birth, and sex. Patients with 
duplicate entries were excluded. The data extract was then exported to the statistical 
program STATA® version 13. The raw data was then inspected for invalid characters, 
outliers and inspected with frequency plots. 
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2.1.4 Data Cleaning and Preparation 
All variables to be included in the uni- and multivariate analysis were identified and 
cleaned as appropriate. All categorical variables were tabulated to identify missing 
values as determined by the size of the final cohort. Continuous variables were plotted 
on histograms to analyse the distribution of values and outliers were identified using 
box and whisker plots and the STATA Version 13 (StataCorp LP, College Station, 
TX) “Hilo” function. Any data entries identified as outliers (e.g. age = “o”, Height 
>2.3 m, Weight >200 kg), were excluded from the final cohort at this stage. Variables 
with missing data were identified and earmarked for imputation. Baseline CD4 count, 
VL, weight and height were collated. These variables were defined as values captured 
within one year (365 days) of starting ART. Baseline BMI was calculated from 
individual weight and height.  
Figure 3. Algorithm for patient collation across medical aid schemes and entry into 
study cohort 
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2.1.5 Cohort description 
The cohort, for the purpose of this study, is defined as all patients registered with AfA 
from the period 01/01/2002 to 31/12/2011. The patient must have initiated ART with 
AfA and been a member of a medical aid scheme in this time period (Fig. 4, below). 
Figure 4. Participant selection and exclusion criteria. 
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2.1.6 Variables and Definitions 
The following variables were extracted from AfA database; sex, date of birth, weight, 
height, Republic of South Africa Identity Number, and date of joining the AfA 
program. 
Longitudinal results for CD4 count and VL, and all medication claims for 
antiretrovirals, and concomitant medicines were extracted. A list of diabetogenic 
drugs was created using a pharmacology reference textbook104 and a review105 (Refer 
to Table 1, pg. 44). Patients were categorized as exposed to diabetogenic drugs if 
they submitted claims for a diabetogenic drug on two or more occasions. 
The ART start date was defined as the date on which antiretroviral drugs were first 
dispensed in the AfA program. The ART starting regimen was the regimen dispensed 
on this date. The baseline CD4 count, VL, and weight were the values measured 
closest to the date of ART initiation, within the 12-month window before the ART 
start date. The primary exposure variable of interest was the NNRTI component of the 
first-line antiretroviral regimen. 
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Table 1. Table of Diabetogenic Drug Classes. 104,105 
2.1.7 Inclusion and Exclusion Criteria 
For this study, all AfA-registered patients were included if they initiated a first-line 
NNRTI-containing ART regimen from January 2002 to December 2011, and were 19 
years or older when starting ART. Patients excluded from the study were those who 
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were already on antidiabetic medication before starting ART, and if they did not have 
a recorded South Africa identification number (as the identification number was used 
to determine if death occurred by linkage with the South African death registry). 
(Refer to Fig. 4, pg. 42).  
2.1.8 Endpoint 
Incident diabetes was defined, using claims data, as the date on which any of the 
antidiabetic agents available in South Africa (insulins, metformin, sulfonylureas, 
alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-IV inhibitors, 
glucagon-like-peptide-1 receptor agonists and meglitinides) were initiated. Patients 
who started and stopped antidiabetic medication in the months around a pregnancy 
(from 6 months before delivery until 1 month after delivery) were assumed to have 
diabetes in pregnancy, and were therefore not included as incident diabetes. 
2.1.9 Imputation of Missing Data 
Some data were missing for baseline CD4 count, baseline VL, baseline weight and 
height (Refer to Table 2, pg. 49 in Results section). Five datasets were imputed with 
the multiple imputation by chained equations (MICE) module in STATA version 13. 
The imputation model included the following variables: sex, baseline weight, height, 
age, CD4 count, and VL, death, incident diabetes, and exposure time. CD4 count and 
VL were actively imputed, and body mass index (BMI) was passively imputed (using 
actively imputed baseline weight and height). The results of the imputation model 
were checked by comparing the imputed data with the actual data.106,107 
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2.1.10 Analysis 
The data for statistical analysis were collated and prepared using a relational database 
(Microsoft SQL Server 2008). The statistical analyses were performed using STATA 
Version 13 (StataCorp LP, College Station, TX) and R version 3.2.1 (R Development 
Core Team). The incidence of diabetes in patients receiving efavirenz-containing 
regimens versus nevirapine-containing regimens was compared with a Kaplan–Meier 
plot and a log-rank test. 
A multivariate Cox-proportional hazards model was conducted to explore the 
association of efavirenz exposure with the hazard of developing diabetes. The 
following variables were adjusted for in the regression model: age, sex, baseline BMI, 
baseline CD4 count, baseline VL, exposure to diabetogenic drugs. For the primary 
analysis, ART was included in the model as time-updated NRTI backbone (AZT-
containing, d4T-containing, or other NRTI combination), and time-updated NNRTI 
(efavirenz or nevirapine); and patients were censored when they died, left the medical 
insurance scheme, switched to PI-based ART, or reached the end of the study period. 
A secondary analysis was conducted to explore incident diabetes within the first ART 
regimen only. For this analysis, two additional reasons for censoring were included: 
NRTI or NNRTI substitution. The effect of including calendar year was explored in 
the multivariate model. The following sensitivity analyses were performed: (i) 
controlling for the competing risk of death, and (ii) a model that excluded patients 
who were virologically-suppressed at baseline. 
The proportional hazards assumption was verified by testing interaction effects of 
analysis time with baseline variables (α=0.05), and graphically in each imputed 
dataset via log–log plots, amongst others. Model selection was performed using the 
Akaike Information Criterion (AIC) after multiple imputation.106,108-110 
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2.1.11 Ethics 
The study protocol was reviewed and approved by the University of Cape Town 
Faculty of Health Sciences Human Research Ethics committee (HREC reference 
number: 282/2011). A copy of the research ethics approval and renewal documents 
are included in Appendix 2. 
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Chapter 3: Results 
Between January 2002 and June 2011, 62,467 patients commenced ART in the AfA 
program, of whom 56,298 patients met the inclusion and exclusion criteria (Fig. 4, 
pg. 42), and were included in the analysis. The demographic and clinical 
characteristics of patients are given in Table 2, pg. 49. Results from the multiple 
imputations for missing covariates are shown in Table 3, pg. 50. Median follow-up 
was 1.56 years (interquartile range (IQR): 0.71– 2.79 years); 21.7% of patients were 
followed up for 3 or more years. 
New onset diabetes was identified in 1,500 (2.66%) patients over 113,297 patient-
years of follow-up (PYFU), giving a crude incidence of 13.24 cases per 1000 PYFU 
(Table 2, pg. 49). There were 17 pregnancy-associated diabetic events, which were 
not included as cases of incident diabetes. Exposure to diabetogenic medicines 
occurred in 19,137 (41.01%) of patients taking efavirenz and 3,643 (37.82%) of 
patients taking nevirapine. The Kaplan Meier analysis of incident diabetes in 
efavirenz versus nevirapine-containing regimens (Fig. 5, pg. 52) demonstrates a 
higher percentage of new onset diabetes in patients receiving efavirenz-containing 
ART; log rank test p value <0.001. The results of the Cox proportional hazard 
regression analyses, including univariate and multivariate analyses and model 
selection, are shown in Table 4, pg. 51. Efavirenz-containing ART was associated 
with a higher risk of developing new-onset diabetes than nevirapine-containing ART, 
adjusted hazard ratio (HR) 1.27 (95% confidence interval (CI): 1.10–1.46). 
Zidovudine and stavudine-containing NRTI backbones, older age at baseline, elevated 
baseline BMI, and exposure to diabetogenic medication were also associated with an 
increased risk of developing diabetes (Table 4, pg. 51). 
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Table 2. Cohort Description. 
50 
Table 3: Results of imputation for baseline variables with missing data. 
51 
Table 4. Univariate, Multivariate, and Model selection results for the Cox regression model of associations with incident diabetes. Drug switches 
within first line regimen included in the model, with censoring at switch to second line therapy. All results are based on multiple imputation. 
52 
No association was found between baseline CD4 and an increased risk of diabetes. 
There was an association between the lowest stratum of baseline VL and an increased 
relative risk for developing diabetes, but no association with higher VL strata. 
The results of the Cox proportional hazard regression analyses where patients were 
censored at the time of first drug switch are shown in Table 5, pg. 53; reasons for 
censoring for this analysis are shown in Table 6, pg. 54. The estimated HRs of the 
variables remained similar after model averaging; confirming the stability of the 
findings.111 These findings did not differ from the regression model with updated 
regimen (censoring at the point of change to second line regimens). Adding calendar 
year to the model did not change the associations observed (Table 7, pg. 55). 
Findings did not change when accounting for competing risk (Table 8, pg. 56). 
Excluding patients with suppressed baseline VLs attenuated the effect of efavirenz on 
incident diabetes somewhat: adjusted HR 1.16; 95% CI: 0.99–1.36. (Table 9, pg. 57).
the chronic inflammatory response to HIV infection,29 which
persists despite effective ART29,30 and the effects of certain
antiretroviral drugs. Our finding that the NRTIs stavudine and
zidovudine were both associated with an increased incidence of
diabetes has previously been reported.2,31 NRTI’s inhibit the
enzyme DNA polymerase-g, responsible for mitochondrial
replication. The dysregulation of mitochondrial function in
different compartments of the body results in various clinical
manifestations of NRTI toxicity, including insulin resistance
and diabetes.32–34 In a prior cross sectional study we found an
increased risk of dysglycemia in South African patients taking
efavirenz compared with those taking nevirapine, but there were
insufficient numbers of cases of diabetes for analysis.14 A small
case–control study from Botswana suggested an association
between efavirenz use and diabetes.35 Randomized controlled
trials showed significantly higher serum glucose concentrations
in participants in the efavirenz arms than the following com-
parator antiretroviral drugs: nevirapine,13 abacavir,13 atazana-
vir,11 atazanavir–ritonavir,9 and raltegravir.12
The mechanism by which efavirenz mediates insulin
resistance and diabetes is unknown. Possible mechanisms
include mitochondrial toxicity36 and toxic effects on adipocytes
and increased rates of lipoatrophy.37,38 Efavirenz causes hepatic
mitochondrial toxicity36 and induces hepatocyte endoplasmic
reticulum stress leading to activation of the unfolded protein
response, and apoptosis.39,40 Efavirenz mediates mitochondrial
toxicity via various mechanisms. Firstly, efavirenz directly
inhibits Complex I of the electron transport chain, resulting
in a markedly reduced mitochondrial transmembrane potential,
thus compromising oxidative phosphorylation and ATP gener-
ation.41–43 Secondly, efavirenz reduces complex IV (COIV)
mRNA (a marker gene of mitochondrial function), and impairs
mitochondrial function in adipocytes.44 Furthermore, efavirenz-
associated mitochondrial dysregulation in adipose tissue causes
impaired adipogenesis, increased lipolysis, and release of free
fatty acids and inflammatory cytokines.44 The increased release
of fatty acids due to adipocyte mitochondrial toxicity are
thought to impair muscle and liver insulin sensitivity, leading
to insulin resistance and diabetes mellitus.45–51 In addition to its
mitochondrial toxicity, efavirenz has been shown to reduce the
secretion of adiponectin (an insulin-sensitizing, antidiabetic
adipokine) by adipocytes.44 We hypothesize that impairment
of mitochondrial bioenergetics and toxicity to adipocytes con-
tributes to the development of diabetes in patients on efavirenz.
By contrast, nevirapine does not appear to exert mitochondrial
toxicity.37,44
Our group have demonstrated a positive correlation
between plasma efavirenz concentrations and both fasting
and 2-hour glucose concentrations after oral glucose tolerance
tests in South African patients.52 People of African origin are
more likely to be genotypic ‘‘slow metabolizers’’ of efavirenz,
which results in elevated efavirenz plasma concentrations, than
people of European descent (20% and 3%, respectively).53
Therefore efavirenz may have a larger diabetogenic effect in
TABLE 2. Results of Imputation for Baseline Variables With Missing Data
Total Cohort
(n¼ 56,298)
Efavirenz-Containing ART
(n¼ 46,666)
Nevirapine-Containing ART
(n¼ 9632)
Variable Mean (95% CI) Mean (95% CI) Mean (95% CI)
Height (m)
Before imputation 164.93 (164.84–165.03) 165.25 (165.18–165.31) 163.14 (162.92–163.35)
After imputation 164.74 (164.64–164.85) 165.14 (165.05–165.23) 163.07 (162.88–163.26)
Weight (kg)
Before imputation 70.34 (70.18–70.51) 69.88 (69.72–70.03) 72.81 (72.39–73.23)
After imputation 70.14 (69.97–70.30) 69.80 (69.62–69.97) 71.59 (71.18–72.00)
CD4 count (cells/ml)
Before imputation 215.82 (214.27–217.38) 208.77 (207.64–209.90) 254.44 (251.66–257.22)
After imputation 215.39 (214.41–216.38) 207.18 (206.12–208.25) 250.26 (247.83–252.69)
Viral load (copies/ml)
Before imputation 4.31 (4.30–4.33) 4.39 (4.38–4.40) 3.88 (3.86–3.90)
After imputation 4.32 (4.31–4.33) 4.38 (4.37–4.39) 3.92 (3.90–3.94)
Body mass index (kg/m2)
Before imputation 25.95 (25.89–26.01) 25.67 (25.62–25.72) 27.44 (27.31–27.56)
After imputation 25.93 (25.87–25.99) 25.68 (25.61–25.75) 27.00 (26.86–27.14)
ART¼ antiretroviral therapy, CI¼ confidence interval.
FIGURE 2. Kaplan–Meier analysis of incident diabetes.
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Figure 5. Kaplan Meier analysis of incident diabetes. 
53 
Table 5. Univariate, Multivariate, and Model selection results for the Cox regression model of associations with incident diabetes 
(censored at first ever drug switch). All results are based on multiple imputation. 
54 
Table 6. Follow up time and censoring reasons when censoring participants at the time of first drug switch. 
55 
Table 7. Multivariate Cox regression model of associations with incident diabetes 
including calendar year. Drug switches within first line regimen included in the 
model, with censoring at switch to second line therapy. All results are based on 
multiple imputation. 
56 
Table 8. Cox proportionate multivariate model censored at first ever drug 
switch, including competing risk. Results are based on multiple imputation. 
57 
Table 9. Univariate, Multivariate, and Model selection results for the Cox regression model of association with incident diabetes, excluding virally 
suppressed patients (VL <400 copies/ml). Drug switches within first line regimen included in the model, with censoring at switch to second line 
therapy. All results are based on multiple imputation. 
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Chapter 4: Discussion 
In this retrospective analysis of 56,298 patients with a median follow up of 1.56 years, 
the crude incidence of diabetes was 13.24 cases per 1000 PYFU, which is at the upper 
end of the range reported from cohort studies in high income countries (4.2–14.1 per 
1000 PYFU).2,16,35,87. Consistent with prior literature, the NRTIs stavudine and 
zidovudine were associated with an increased incidence of diabetes. In addition, use 
of efavirenz was associated with a significantly higher incidence of diabetes than 
nevirapine in this large cohort of South African patients. To the best of my 
knowledge, this is the first cohort study that shows an increased risk of diabetes from 
efavirenz use in first-line ART. 
These findings have important implications for LMICs, which are facing a 
burgeoning diabetes epidemic, as efavirenz is the preferred NNRTI in first-line ART, 
zidovudine is recommended in second line ART, and many people are still taking 
stavudine, even though it is no longer recommended by the WHO.101 
HIV-infected patients have an estimated 4-fold greater relative risk of developing 
diabetes than the HIV-uninfected population.35 Factors contributing to the increased 
risk of diabetes in people with HIV include, insulin resistance due to the chronic 
inflammatory response to HIV infection,112 which persists despite effective ART112,113
and the effects of certain antiretroviral drugs. The finding that the NRTIs stavudine 
and zidovudine were both associated with an increased incidence of diabetes has 
previously been reported.2,19 NRTIs inhibit the enzyme DNA polymerase-γ, 
responsible for mitochondrial replication. The dysregulation of mitochondrial 
function in different compartments of the body results in various clinical 
manifestations of NRTI toxicity, including insulin resistance and diabetes.28,114,115 In a 
59 
prior cross sectional study, Dave et al, 2011, found an increased risk of dysglyacemia 
in South African patients taking efavirenz compared with those taking nevirapine, but 
there were insufficient numbers of cases of diabetes for analysis.4 A small case–
control study from Botswana suggested an association between efavirenz use and 
diabetes.57 Randomized controlled trials showed significantly higher serum glucose 
concentrations in participants in the efavirenz arms than the following comparator 
antiretroviral drugs: nevirapine,58 abacavir,58 atazanavir,59 atazanavir–ritonavir,60  and   
raltegravir.61 
The mechanism by which efavirenz mediates insulin resistance and diabetes is 
unknown. Possible mechanisms include mitochondrial toxicity62 and toxic effects on 
adipocytes and increased rates of lipoatrophy.63,64 Efavirenz causes hepatic 
mitochondrial toxicity62 and induces hepatocyte endoplasmic reticulum stress leading 
to activation of the unfolded protein response, and apoptosis.116,117 Efavirenz mediates 
mitochondrial toxicity via various mechanisms. Firstly, efavirenz directly inhibits 
Complex I of the electron transport chain, resulting in a markedly reduced 
mitochondrial transmembrane potential, thus compromising oxidative 
phosphorylation and ATP generation.65-67 Secondly, efavirenz reduces complex IV 
(COIV) mRNA (a marker gene of mitochondrial function), and impairs mitochondrial 
function in adipocytes.68 Furthermore, efavirenz associated mitochondrial 
dysregulation in adipose tissue causes impaired adipogenesis, increased lipolysis, and 
release of free fatty acids and inflammatory cytokines.68 The increased release of fatty 
acids due to adipocyte mitochondrial toxicity are thought to impair muscle and liver 
insulin sensitivity, leading to insulin resistance and diabetes mellitus.45,69-74 In 
addition to its mitochondrial toxicity, efavirenz has been shown to reduce the 
secretion of adiponectin (an insulin-sensitizing, antidiabetic adipokine) by 
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adipocytes.68 It is therefore hypothesized that impairment of mitochondrial 
bioenergetics and toxicity to adipocytes contributes to the development of diabetes in 
patients on efavirenz. By contrast, nevirapine does not appear to exert mitochondrial 
toxicity.63,68 
A prior cross sectional study demonstrated a positive correlation between plasma 
efavirenz concentrations and both fasting and 2-hour glucose concentrations after oral 
glucose tolerance tests in South African patients.118 People of African origin are more 
likely to be genotypic ‘‘slow metabolizers’’ of efavirenz, which results in elevated 
efavirenz plasma concentrations, than people of European descent (20% and 3%, 
respectively).76 Therefore, efavirenz may have a larger diabetogenic effect in 
Africans, which may explain why, in contrast with the findings of this analysis, 
studies from high-income countries have not found an association between efavirenz 
and diabetes. 
In this analysis, increasing age, and male sex were associated with an increased risk 
of diabetes, which is consistent with findings of other studies.2,15,31,40,112,119-121 There 
was no demonstrable association between baseline CD4 count and diabetes, which is 
similar to that reported by a French cohort,16 but other studies have found an 
increased risk of diabetes with lower CD4 counts.112,119  
The relationship between CD4 count and incident diabetes remains unresolved. Some 
studies suggest that activated CD4 cells are integral in non-insulin mediated glucose 
disposal.122 The association of dysglycaemia and low CD4 count may therefore be 
explained by impaired non-insulin mediated glucose disposal attributable to a reduced 
reserve of CD4 cells and elevated levels of systemic inflammation.122,123 Other studies 
suggest that autoimmune diabetes occurs in patients post ART initiation where it has 
been demonstrated that antibodies to glutamic acid decarboxylase develop, coinciding 
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with rapid increases in CD4 count, inducing a form of type 1 diabetes.124,125 
Alternatively, there may be defective glucose disposal at high CD4 counts due to 
post-ART recovery of CD4 cells, that are functionally unable to utilize glucose 
efficiently because of low GLUT-1 or interleukin 7 receptor expression.122,126 The 
relationship between CD4 count and dysglycaemia may also be complicated by ethnic 
influences on varying responses to immune reconstitution and the subsequent risk of 
developing diabetes.122 The associations between CD4 and incident diabetes are 
tenuous are require further exploration.  
In this study, there was an association between the lowest stratum of baseline VL and 
an increased relative risk for developing diabetes, but no association with higher VL 
strata. The French cohort reported no association between VL and diabetes.16 In 
contrast, other studies have found an association between high VLs and diabetes.15,112 
The association observed between low baseline VLs and increased risk of diabetes 
may be attributed to the inclusion of patients already on undisclosed ART on entry to 
the AfA program.  
This study has several limitations. A minority of patients in South Africa 
(approximately 18 percent) have access to medical aid schemes, especially amongst 
the HIV-infected population. Patients within these medical aid schemes may represent 
a population with higher socioeconomic status and characteristics not generalizable to 
patients treated in the public sector. Patients receiving care from funded schemes may 
have had closer/ less close follow up with different rates of loss-to –follow up than 
their public sector counter parts. Adherence may differ from public sector patients.  
However, it is important to note that patients in the medical schemes were treated in 
accordance WHO guidelines for resource limited settings, with regimens and 
62 
monitoring that is similar to patients in the public sector. Only baseline data was used 
for this analysis, as no follow up data was available. It was therefore not possible to 
adjust for weight changes during follow-up. This is a significant limitation as trends 
in weight gain post-ART initiation are important factors in the development of insulin 
resistance and diabetes mellitus. Similarly, there was no follow up CD4 and VL data, 
which potentially serve as adherence markers. As such, there was no reliable indicator 
of adherence in this study.  Furthermore, there was a significant amount of missing 
baseline data, notably of weight and height, 26.7% and 33.8% respectively. However, 
missing data was imputed, which is known to be superior to using complete case 
analysis.127,128 Notably, ART exposure may have occurred before commencing ART 
within the AfA program and there were 18.8% of patients with a suppressed VL at 
baseline, which is likely due to undisclosed ART use. In a sub-analysis, excluding 
virally suppressed patients at baseline (VL <400copies/ml) diminishes the effect of 
efavirenz on incident diabetes; adjusted HR 1.16; 95% CI: 0.99 -1.36 (Table 9, pg. 
57). The inclusion of virally suppressed patients in the analysis reflects a critical 
limitation of the cohort and that the relationship between efavirenz and incident 
diabetes is rather modest and elucidated due to the large sample size in this study. 
The determination of incident diabetes was based on initiation of diabetes therapy, as 
the results of plasma glucose or glycated haemoglobin are not captured in the 
database. It is therefore possible that cases of diabetes that were only treated with 
lifestyle modifications were missed. As patients were not routinely screened for 
diabetes at the time of ART initiation, some patients may have entered the cohort with 
undiagnosed diabetes. A further limitation, in common with other studies, was the 
lack of an internal control (HIV-uninfected population) prohibiting the estimation of 
the relative risk of diabetes. A further limitation is that a propensity score was not 
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utilized to adjust for changes in drug regimen prescribing trends that occurred in 
accordance with health policy changes over the study period.  
Future studies with longer follow-up utilizing a control group, time-updated BMI, 
CD4 and VL, will allow better characterization of risk factors associated with diabetes 
in the ART treated population. Studies with internal controls may better investigate 
the effect of ART and disorders of glucose metabolism by controlling for the effect of 
age, a major risk factor for diabetes. Further studies are required to investigate the 
effect of PI based therapy (currently reserved as second line agents) and the incidence 
of diabetes in the SSA population.  
A strength of this study is that the use of diabetogenic medication was adjusted for in 
the multivariate model, and was associated with a 53% increase in the relative risk of 
diabetes. 
In conclusion, exposure to efavirenz, stavudine, and zidovudine was associated with 
an increased incidence of diabetes. Although the increased risk of diabetes with these 
antiretrovirals was relatively modest, the large African patient population exposed to 
ART for prolonged periods means that the findings of this study has important public 
health implications. While screening for diabetes should be increased in people on 
long-term ART, consideration should be given to using antiretrovirals with less risk of 
metabolic complications. Further studies to confirm the association of efavirenz and 
risk of diabetes should be conducted in LMICs, and the molecular mechanisms of 
efavirenz-induced dysglycaemia need further investigation. 
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Chapter 5: Conclusions 
In this retrospective analysis of a cohort, with a median 1.56-year period of follow-up, 
there appears to be a significant risk for the development of diabetes whilst on ART. 
This risk is greater than the general population. There appears to be added risk of 
developing diabetes whilst on efavirenz-containing ART. The main factors 
contributing to the development of diabetes appears to be advancing age and 
increased time exposure to ART. The above has pertinent implications for the 
continued management of HIV infected patients, as efavirenz is the preferred NNRTI 
component due to its lower potential for hepatotoxicity, drug interaction profile, cost 
and patient compliance. Further investigation and expansion of the regression models 
evaluating the efavirenz-diabetes association are however warranted.  
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Abstract: Efavirenz is the preferred nonnucleoside reverse transcrip-
tase inhibitor (NNRTI) in first-line antiretroviral therapy (ART) regi-
mens in low- and middle-income countries, where the prevalence of
diabetes is increasing. Randomized control trials have shown mild
increases in plasma glucose in participants in the efavirenz arms, but
no association has been reported with overt diabetes. We explored the
association between efavirenz exposure and incident diabetes in a large
Southern African cohort commencing NNRTI-based first-line ART.
Our cohort included HIV-infected adults starting NNRTI-based ART
in a private sector HIV disease management program from January 2002
to December 2011. Incident diabetes was identified by the initiation of
diabetes treatment. Patients with prevalent diabetes were excluded.
We included 56,298 patients with 113,297 patient-years of follow-up
(PYFU) on first-line ART. The crude incidence of diabetes was 13.24 per
1000 PYFU. Treatment with efavirenz rather than nevirapine was
associated with increased risk of developing diabetes (hazard ratio
1.27 (95% confidence interval (CI): 1.10–1.46)) in a multivariate
analysis adjusting for age, sex, body mass index, baseline CD4 count,
viral load, NRTI backbone, and exposure to other diabetogenic medi-
cines. Zidovudine and stavudine exposure were also associated with an
increased risk of developing diabetes.
We found that treatment with efavirenz, as well as stavudine and
zidovudine, increased the risk of incident diabetes. Interventions to detectomi S. Levitt, MBC (SA),
ed(Clin Pharm), MSc(Epid)
(Medicine 95(9):e2844)
Abbreviations: AfA = Aid for AIDS, AIC = Akaike Information
Criterion, ART = antiretroviral therapy, AZT = zidovudine, BMI =
body mass index, d4T = stavudine, EFV = efavirenz, HIV = human
immunodeficiency virus, HR = hazard ratio, IQR = interquartile
range, LMICs = low- and middle-income countries, NNRTI =
nonnucleoside reverse transcriptase inhibitor, NRTIs = nucleoside
reverse transcriptase inhibitors, NVP = nevirapine, PI = protease
inhibitor, PYFU = patient-years of follow-up, VL = viral load,
WHO = World Health Organization.
INTRODUCTION
A ccess to antiretroviral therapy (ART) has considerablyreduced morbidity and mortality associated with human
immunodeficiency virus (HIV) infection. However, long-term
ART is associated with adverse metabolic effects including
dysglycemia and new onset diabetes mellitus.1,2 With the
prevalence of noncommunicable diseases, including diabetes,
increasing in low- and middle-income countries (LMICs),3
patients on ART in LMICs face a dual burden of disease.4
A number of antiretroviral drugs are known to cause
diabetes, including the nucleoside reverse transcriptase inhibi-
tors (NRTIs) stavudine (d4T) and zidovudine (AZT),2 and
the older protease inhibitors (PIs) indinavir5 and ritonavir.6,7
Efavirenz, which is now the preferred nonnucleoside
reverse transcriptase inhibitor (NNRTI) for first-line ART in
LMICs,8 is associated with slight increases in blood glucose in
randomized controlled trials,9–13 and, in one study conducted
by our group.14 However, there is no good evidence that
efavirenz is associated with an increased risk of developing
diabetes.
The aim of our study was to investigate the association
between efavirenz use and the incidence of diabetes mellitus in
a South African cohort of patients on first-line ART.
METHODS
Study Population and Data Source
The study population comprises South African HIV-
infected adults enrolled in a private sector HIV disease manage-
ment program, Aid for AIDS (AfA). The AfA program collects
demographic, laboratory, and clinical data on individuals who
registered for HIV benefits. Claim data were captured by AfA
from the medical insurance fund claim database. These includeion, pharmacy, and medical practitioner
bmitted to the scheme for processing
e service by the provider (eg, pharmacy,
www.md-journal.com | 1
hospitalization) for direct reimbursement or after the service
date by the member where the member had already paid the
claim. Reimbursement was subject to established AfA proto-
cols, including protocols for ART initiation, change of ART
regimen, and the treatment of certain opportunistic infections.
No copayment was required for ART, viral load (VL) and CD4
monitoring, and doctor visits.
Despite being a private sector program, AfA standardized
guidelines for HIVmanagement, are similar to theWorld Health
Organization (WHO) guidelines for LMICs.8 Patients were
eligible for ART initiation if their CD4 cell count was below
350 cells/ml or they hadWHO stage 3 or 4 illness irrespective of
the CD4 count. The recommended initial regimen was a com-
bination of 2 NRTIs and an NNRTI. VL and CD4 counts were
monitored every 6 months.
Data linkage to the South Africa death registry allowed
ascertainment of deaths and date of death, as previously
described.15,16
Variables and Definitions
We extracted sex, date of birth, weight, height, Republic of
South Africa Identity Number, and date of joining the AfA
program from the form completed by the doctor on registering
the patient with AfA.
We extracted longitudinal results for CD4 count and VL,
and all medication claims for antiretrovirals and concomitant
medicines. We created a list of diabetogenic drugs using a
pharmacology reference textbook17 and a review18 (see
Appendix 1, http://links.lww.com/MD/A735). We categorized
patients as exposed to diabetogenic drugs if they submitted
claims for a diabetogenic drug on 2 or more occasions.
We defined the ART start date as the date on which anti-
retroviral drugs were first dispensed in theAfA program. TheART
starting regimen was the regimen dispensed on this date. The
baseline CD4 count, VL, and weight were the values measured
closest to the date of ART initiation, within the 12-month window
before theARTstart date. The primary exposurevariable of interest
was the NNRTI component of the first-line antiretroviral regimen.
Inclusion and Exclusion Criteria
For this study we included AfA-registered patients who
initiated a first-line NNRTI-containing ART regimen from
January 2002 to December 2011 and were 19 years or older
when starting ART. We excluded patients already on antidia-
betic medication before starting ART, and patients with missing
South Africa identification numbers (as the identification num-
ber was used to determine if death occurred by linkage with the
South African death registry).
Endpoint
Incident diabetes was defined, using claims data, as the date
on which any of the antidiabetic agents available in South Africa
(insulins, metformin, sulfonylureas, alpha glucosidase inhibitors,
thiazolidinediones, dipeptidyl peptidase-IV inhibitors, glucagon-
like-peptide-1 receptor agonists and meglitinides) were initiated.
Patients who started and stopped antidiabetic medication in the
months around a pregnancy (from 6 months before delivery until
1 month after delivery) were assumed to have diabetes in preg-
nancy and were therefore not included as incident diabetes.
Karamchand et alImputation of Missing Data
Some data were missing for baseline CD4 count, baseline
VL, baseline weight and height (see Table 1). We imputed
2 | www.md-journal.com5 datasets with the multiple imputation by chained equations
(MICE) module in STATA version 13. The imputation model
included the following variables: sex, baseline weight, height,
age, CD4 count, and VL, death, incident diabetes, and exposure
time. CD4 count and VL were actively imputed, and body mass
index (BMI) was passively imputed (using actively imputed
baseline weight and height). We checked the results of the
imputation model by comparing the imputed data with the
actual data.19,20
Analysis
We collated and prepared the data for statistical analysis
using a relational database (Microsoft SQL Server 2008). We
used STATA Version 13 (StataCorp LP, College Station, TX)
and R version 3.2.1 (R Development Core Team) for statistical
analyses.21 We compared the incidence of diabetes in patients
receiving efavirenz-containing regimens versus nevirapine-con-
taining regimens with a Kaplan–Meier plot and a log-rank test.
We explored the association of efavirenz exposure with
the hazard of developing diabetes using a multivariate Cox-
proportional hazards model. We adjusted for the following
variables: age, sex, baseline BMI, baseline CD4 count, baseline
VL, exposure to diabetogenic drugs. For the primary analysis
ARTwas included in the model as time-updated NRTI backbone
(AZT-containing, d4T-containing, or other NRTI combination)
and time-updated NNRTI (efavirenz or nevirapine); and patients
were censored when they died, left the medical insurance
scheme, switched to PI-based ART, or reached the end of the
study period. We performed a secondary analysis exploring
incident diabetes within the first ART regimen only. For this
analysis we included 2 additional reasons for censoring: NRTI
or NNRTI substitution. We explored the effect of including
calendar year in the multivariate model. We performed the
following sensitivity analyses: we controlled for the competing
risk of death, we constructed a model excluding patients
virologically suppressed at baseline.
The proportional hazards assumption was verified by
testing interaction effects of analysis time with baseline vari-
ables (a¼ 0.05), and graphically in each imputed dataset via
log–log plots, amongst others. We performed model selection
using the Akaike Information Criterion (AIC) after multiple
imputation.19,22–24
Ethics
The study protocol was reviewed and approved by the
University of Cape Town Faculty of Health Sciences Human
Research Ethics committee.
RESULTS
Between January 2002 and June 2011, 62,467 patients
commenced ART in the AfA program, of whom 56,298 patients
met our inclusion and exclusion criteria (Figure 1) and were
included in the analysis. The demographic and clinical charac-
teristics of patients are given in Table 1. Results from the
multiple imputations for missing covariates are shown in
Table 2. Median follow-up was 1.56 years (interquartile range
(IQR): 0.71–2.79 years), 21.7% of patients were followed up
for 3 or more years.
We identified new onset diabetes in 1500 (2.66%) patients
over 113,297 patient-years of follow-up (PYFU), giving a crude
Medicine  Volume 95, Number 9, March 2016incidence of 13.24 cases per 1000 PYFU (Figure 2). There
were 17 pregnancy-associated diabetic events, which were not
included as cases of incident diabetes. Exposure to diabetogenic
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Cohort Description
Whole Cohort Efavirenz-Containing ART Nevirapine-Containing ART
Number of patients 56,298 46,666 9632
Age (yr)
Median (IQR) 38.14 (33.15–44.26) 39.1 (34.1–45.17) 34.05 (29.99–38.65)
Sex
Male 20,224 (35.92) 18,822 (40.33%) 1402 (14.55%)
Female 36,074 (64.08) 27,844 (59.67%) 8230 (85.44%)
Race
Asian 148 (0.26%) 126 (0.27%) 22 (0.23%)
Black 53,270 (94.62%) 44,179 (94.67%) 9091 (94.38%)
Mixed 768 (1.36%) 628 (1.35%) 140 (1.45%)
White 989 (1.76%) 825 (1.77%) 164 (1.7%)
Not reported 1123 (1.99%) 908 (1.95%) 215 (2.23%)
Nucleoside reverse transcriptase inhibitor
(initial regimen containing)
Zidovudine 26,917 (47.81%) 25,329 (54.28%) 1588 (16.49%)
Stavudine 22,465 (39.9%) 16,002 (34.29%) 6463 (67.1%)
Other 6916 (12.28%) 5335 (11.43%) 1581 (16.41%)
Exposure to other diabetogenic drugs 22,780 (40.46%) 19,137 (41.01%) 3643 (37.82%)
Baseline height (m)
Median (IQR) 165 (160–170) 165 (160–170) 163 (158–168)
Missing 19,033 (33.81%) 15,390 (32.98%) 3643 (37.82%)
Baseline weight (kg)
Median (IQR) 68 (60–79) 68 (60–79) 70 (62–81)
Missing 15,042 (26.72%) 12,349 (26.46%) 2693 (27.96%)
Baseline body mass index (kg/m2)
Median (IQR) 25.06 (21.97–29.00) 24.82 (21.80–28.69) 26.52 (23.14–30.49)
Missing 23,178 (41.17%) 18,776 (40.23%) 4402 (45.7%)
Baseline CD4 count (cells/ml)
Median (IQR) 181 (88–280) 176 (81–277) 201 (121–306)
Missing 948 (1.68%) 769 (1.65%) 179 (1.86%)
Baseline log viral load (copies/ml)
Median (IQR) 4.78 (3.66–5.37) 4.87 (3.86–5.43) 4.35 (2.59–5.03)
Missing 3464 (6.15%) 2845 (6.1%) 619 (6.43%)
Follow-up time (yr)
Median (IQR) 1.56 (0.71–2.79) 1.50 (0.67–2.69) 1.90 (0.93–3.34)
Patient years 113,297 89,915 23,382
3 or more years of NNRTI exposure 21.70% 29.86% 20.66%
Reason for censoring
Diabetes 1500 (2.66%) 1257 (2.69%) 243 (2.52%)
Switch to PI 3706 (6.58%) 2778 (5.95%) 928 (9.63%)
Study end 40,785 (72.44%) 34,186 (73.26%) 6599 (68.51%)
Death 1774 (3.15%) 1488 (3.19%) 286 (2.97%)
Left scheme 8533 (15.16%) 6957 (14.91%) 1576 (16.36%)
Crude diabetes incidence
Events/1000 patient years 13.24 13.98 10.39
nnu
Medicine  Volume 95, Number 9, March 2016 Patients Taking NNRTI-Based ART: Diabetes Risk Factorsmedicines occurred in 19,137 (41.01%) of patients taking
efavirenz and 3643 (37.82%) of patients taking nevirapine.
The Kaplan Meier analysis of incident diabetes in efavirenz
versus nevirapine-containing regimens is shown in Figure 2.
The results of the Cox proportional hazard regression
analyses, including univariate and multivariate analyses and
model selection, are shown in Table 3. Efavirenz-containing
ART was associated with a higher risk of developing new-onset
ART¼ antiretroviral therapy, IQR¼ interquartile range, NNRTI¼ nodiabetes than nevirapine-containing ART, adjusted hazard ratio
(HR) 1.27 (95% confidence interval (CI): 1.10–1.46). Zidovu-
dine and stavudine-containing NRTI backbones, older age at
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.baseline, elevated baseline BMI, and exposure to diabetogenic
medication were also associated with an increased risk of
developing diabetes. We found no association between baseline
CD4 and an increased risk of diabetes.
The results of the Cox proportional hazard regression
analyses where we censored patients at the time of first
drug switch are shown in Table 4; reasons for censoring
for this analysis are shown in Supplementary Table 1, http://
cleoside reverse transcriptase inhibitor, PI¼ protease inhibitor.links.lww. com/MD/A736. The estimated HRs of the variables
remained similar after model averaging, confirming the stability
of our findings.25 These findings did not differ from the
www.md-journal.com | 3
Karamchand et al Medicine  Volume 95, Number 9, March 2016regression model with updated regimen (censoring at the point
of change to second line regimens). Adding calendar year to the
model did not change the associations observed (Supplementary
Table 2, http://links.lww.com/MD/A736). Findings did not
change when we accounted for competing risk (Supplementary
Table 3, http://links.lww.com/MD/A736). Excluding patients
with suppressed baseline VLs attenuated the effect of efavirenz
FIGURE 1. Participant selection and exclusion criteria.on incident diabetes somewhat: adjusted HR 1.16; 95% CI:
0.99–1.36 (Supplementary Table 4, http://links.lww.com/MD/
A736).
DISCUSSION
We found efavirenz use to be associated with a signifi-
cantly higher incidence of diabetes than nevirapine in a large
cohort of South African patients. To the best of our knowledge,
4 | www.md-journal.comthis is the first cohort study to show an increased risk of diabetes
from efavirenz use in first-line ART. We also found that the
NRTIs stavudine and zidovudine were associated with an
increased incidence of diabetes. These findings have important
implications for LMICs, which are facing a burgeoning diabetes
epidemic, as efavirenz is the preferred NNRTI in first-line ART,
zidovudine is recommended in second line ART, and many
people are still taking stavudine, even though it is no longer
recommended by the WHO.8
HIV-infected patients have an estimated 4-fold greater
relative risk of developing diabetes than the HIV-uninfected
population.26 We found a crude incidence of diabetes of 13.24
per 1000 PYFU, which is at the upper end of the range reported
from cohort studies in high income countries (4.2–14.1 per
1000 PYFU).2,26–28 Factors contributing to the increased risk of
diabetes in people with HIV include insulin resistance due to
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Results of Imputation for Baseline Variables With Missing Data
Total Cohort
(n¼ 56,298)
Efavirenz-Containing ART
(n¼ 46,666)
Nevirapine-Containing ART
(n¼ 9632)
Variable Mean (95% CI) Mean (95% CI) Mean (95% CI)
Height (m)
Before imputation 164.93 (164.84–165.03) 165.25 (165.18–165.31) 163.14 (162.92–163.35)
After imputation 164.74 (164.64–164.85) 165.14 (165.05–165.23) 163.07 (162.88–163.26)
Weight (kg)
Before imputation 70.34 (70.18–70.51) 69.88 (69.72–70.03) 72.81 (72.39–73.23)
After imputation 70.14 (69.97–70.30) 69.80 (69.62–69.97) 71.59 (71.18–72.00)
CD4 count (cells/ml)
Before imputation 215.82 (214.27–217.38) 208.77 (207.64–209.90) 254.44 (251.66–257.22)
After imputation 215.39 (214.41–216.38) 207.18 (206.12–208.25) 250.26 (247.83–252.69)
Viral load (copies/ml)
Before imputation 4.31 (4.30–4.33) 4.39 (4.38–4.40) 3.88 (3.86–3.90)
After imputation 4.32 (4.31–4.33) 4.38 (4.37–4.39) 3.92 (3.90–3.94)
Body mass index (kg/m2)
Before imputation 25.95 (25.89–26.01) 25.67 (25.62–25.72) 27.44 (27.31–27.56)
After imputation 25.93 (25.87–25.99) 25.68 (25.61–25.75) 27.00 (26.86–27.14)
Medicine  Volume 95, Number 9, March 2016 Patients Taking NNRTI-Based ART: Diabetes Risk Factorsthe chronic inflammatory response to HIV infection,29 which
persists despite effective ART29,30 and the effects of certain
antiretroviral drugs. Our finding that the NRTIs stavudine and
zidovudine were both associated with an increased incidence of
diabetes has previously been reported.2,31 NRTI’s inhibit the
enzyme DNA polymerase-g, responsible for mitochondrial
replication. The dysregulation of mitochondrial function in
different compartments of the body results in various clinical
manifestations of NRTI toxicity, including insulin resistance
and diabetes.32–34 In a prior cross sectional study we found an
increased risk of dysglycemia in South African patients taking
efavirenz compared with those taking nevirapine, but there were
insufficient numbers of cases of diabetes for analysis.14 A small
ART¼ antiretroviral therapy, CI¼ confidence interval.case–control study from Botswana suggested an association
between efavirenz use and diabetes.35 Randomized controlled
trials showed significantly higher serum glucose concentrations
FIGURE 2. Kaplan–Meier analysis of incident diabetes.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in participants in the efavirenz arms than the following com-
parator antiretroviral drugs: nevirapine,13 abacavir,13 atazana-
vir,11 atazanavir–ritonavir,9 and raltegravir.12
The mechanism by which efavirenz mediates insulin
resistance and diabetes is unknown. Possible mechanisms
include mitochondrial toxicity36 and toxic effects on adipocytes
and increased rates of lipoatrophy.37,38 Efavirenz causes hepatic
mitochondrial toxicity36 and induces hepatocyte endoplasmic
reticulum stress leading to activation of the unfolded protein
response, and apoptosis.39,40 Efavirenz mediates mitochondrial
toxicity via various mechanisms. Firstly, efavirenz directly
inhibits Complex I of the electron transport chain, resulting
in a markedly reduced mitochondrial transmembrane potential,
thus compromising oxidative phosphorylation and ATP gener-
ation.41–43 Secondly, efavirenz reduces complex IV (COIV)
mRNA (a marker gene of mitochondrial function), and impairs
mitochondrial function in adipocytes.44 Furthermore, efavirenz-
associated mitochondrial dysregulation in adipose tissue causes
impaired adipogenesis, increased lipolysis, and release of free
fatty acids and inflammatory cytokines.44 The increased release
of fatty acids due to adipocyte mitochondrial toxicity are
thought to impair muscle and liver insulin sensitivity, leading
to insulin resistance and diabetes mellitus.45–51 In addition to its
mitochondrial toxicity, efavirenz has been shown to reduce the
secretion of adiponectin (an insulin-sensitizing, antidiabetic
adipokine) by adipocytes.44 We hypothesize that impairment
of mitochondrial bioenergetics and toxicity to adipocytes con-
tributes to the development of diabetes in patients on efavirenz.
By contrast, nevirapine does not appear to exert mitochondrial
toxicity.37,44
Our group have demonstrated a positive correlation
between plasma efavirenz concentrations and both fasting
and 2-hour glucose concentrations after oral glucose tolerance
tests in South African patients.52 People of African origin are
more likely to be genotypic ‘‘slow metabolizers’’ of efavirenz,
which results in elevated efavirenz plasma concentrations, than
people of European descent (20% and 3%, respectively).53
Therefore efavirenz may have a larger diabetogenic effect in
www.md-journal.com | 5
TABLE 3. Univariate, Multivariate, and Model Selection Results for the Cox Regression Model of Associations With Incident
Diabetes
Univariate Multivariate
Variable Category HR (95% CI) P HR (95% CI) P Model Selection (AIC)
Nonnucleoside reverse
transcriptase inhibitor
Efavirenz
Nevirapine
1.40 (1.22–1.60)
Referent
<0.001 1.27 (1.10–1.47)
Referent
0.001 1.27 (1.10–1.46)
Referent
Nucleoside reverse
transcriptase inhibitor
Zidovudine
Stavudine
1.30 (1.15–1.46)
1.53 (1.32–1.78)
<0.001
<0.001
1.35 (1.19–1.52)
1.60 (1.38–1.87)
<0.001
<0.001
1.37 (1.21–1.54)
1.64 (1.41–1.91)
Other Referent Referent Referent
Exposure to other
diabetogenic drugs
1.68 (1.51–1.86) <0.001 1.53 (1.37–1.70) <0.001 1.53 (1.38–1.71)
Baseline age (yr) 19–24 0.35 (0.20–0.60) <0.001 0.47 (0.27–0.81) 0.007 0.46 (0.27–0.80)
25–34 0.64 (0.56–0.73) <0.001 0.71 (0.62–0.82) <0.001 0.71 (0.62–0.81)
35–44 Referent Referent Referent
45–54 1.50 (1.33–1.70) <0.001 1.38 (1.21–1.56) <0.001 1.36 (1.20–1.54)
55 1.86 (1.50–2.31) <0.001 1.64 (1.32–2.04) <0.001 1.57 (1.26–1.95)
Sex Male 1.41 (1.27–1.56) <0.001 1.47 (1.32–1.64) <0.001 1.44 (1.29–1.61)
Female Referent Referent Referent
Baseline body mass index
(BMI) quartile (kg/m/m)
10–17
18–24
0.38 (0.23–0.63)
0.65 (0.58–0.74)
0.001
<0.001
0.33 (0.19–0.56)
0.61 (0.53–0.69)
0.001
<0.001
0.32 (0.19–0.55)
0.60 (0.53–0.69)
25–34 Referent Referent Referent
35þ 1.45 (1.16–1.81) 0.002 1.58 (1.26–1.97) <0.001 1.58 (1.27–1.97)
Baseline CD4 count (cells/ml) 0–199 1.04 (0.92–1.17) 0.534 1.08 (0.95–1.23) 0.220
200–349 Referent Referent Excluded by AIC
350þ 1.25 (1.06–1.47) 0.007 1.10 (0.91–1.34) 0.324
Baseline viral load (copies/ml) 0–999 1.31 (1.14–1.51) <0.001 1.24 (1.05–1.47) 0.011 1.28 (1.11–1.47)
1000–99,999 Referent Referent Referent
100,000–999,999 1.07 (0.95–1.21) 0.261 1.03 (0.91–1.16) 0.674 1.03 (0.91–1.17)
1,000,000 1.15 (0.89–1.48) 0.285 1.15 (0.89–1.49) 0.278 1.14 (0.89–1.48)
Drug switches within first-line regimen included in the model, with censoring at switch to second line therapy. All results are based on multiple
imputations.
AIC¼Akaike Information Criterion, CI¼ confidence interval, HR¼ hazard ratio.
Karamchand et al Medicine  Volume 95, Number 9, March 2016Africans, which may explain why, in contrast with our findings,
studies from high income countries have not found an associ-
ation between efavirenz and diabetes.
Our finding that increasing age, and male sex were associ-
ated with an increased risk of diabetes is consistent with
findings of other studies.2,29,54–59 We could not show any
association between baseline CD4 count and diabetes, which
is similar to that reported by a French cohort,27 but other studies
have found an increased risk of diabetes with lower CD4
counts.29,54 We found an association between the lowest stra-
tum of baseline VL and an increased relative risk for developing
diabetes, but no association with higher VL strata. The French
cohort reported no association between VL and diabetes.27 In
contrast, other studies have found an association between high
VLs and diabetes.29,58 The association we observed between
low baseline VLs and increased risk of diabetes may be
attributed to the inclusion of patients already on undisclosed
ART on entry to the AfA program.
Our study has limitations. We had missing baseline data,
notably of BMI. However, we imputed missing data, which are
known to be superior to using complete case analysis.60,61 ART
exposure may have occurred before commencing ART within
the AfA program and there were 18.8% of patients with a
suppressed VL at baseline, which is likely due to undisclosed
6 | www.md-journal.comART use. We identified incident diabetes based on initiation of
diabetes therapy as the results of plasma glucose or glycated
hemoglobin are not captured in the database. We will therefore
have missed cases of diabetes that were only treated with
lifestyle modifications. As patients were not routinely screened
for diabetes at the time of ART initiation, some patients may
have entered the cohort with undiagnosed diabetes. We could
not adjust for weight changes during follow-up in our analyses,
as weight is only recorded at baseline. A strength of our study is
that we adjusted for the concurrent use of diabetogenic medi-
cation in the multivariate model, which was associated with a
53% increase in the relative risk of diabetes.
In conclusion, we found that exposure to efavirenz, stavu-
dine, and zidovudine was associated with an increased incidence
of diabetes. Although the increased risk of diabetes with these
antiretrovirals was relatively modest, the large African patient
population exposed to ART for prolonged periods means that our
findinghas important public health implications.While screening
for diabetes should be increased in people on long-term ART,
consideration should be given to using antiretrovirals with less
risk of metabolic complications. Further studies to confirm the
association of efavirenz and risk of diabetes should be conducted
in LMICs, and the molecular mechanisms of efavirenz-induced
dysglycemia need further investigation.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Univariate, Multivariate, and Model Selection Results for the Cox Regression Model of Associations With Incident
Diabetes (Censored at First Ever Drug Switch)
Univariate
Multivariate
(Rubins Rule)
Model Selection
(AIC)
Variable Category HR (95% CI) P HR (95% CI) P HR (95% CI)
Nonnucleoside reverse
transcriptase inhibitor
Efavirenz
Nevirapine
1.38 (1.18–1.60)
Referent
<0.001 1.26 (1.07–1.49)
Referent
0.005 1.33 (1.13–1.56)
Referent
Nucleoside reverse
transcriptase inhibitor
Zidovudine
Stavudine
1.34 (1.17–1.54)
1.62 (1.37–1.90)
<0.001
<0.001
1.39 (1.21–1.60)
1.67 (1.41–1.98)
<0.001
<0.001
1.57 (1.37–1.80)
1.96 (1.66–2.32)
Other Referent Referent Referent
Exposure to other
diabetogenic drugs
1.68 (1.50–1.88) <0.001 1.52 (1.36–1.71) <0.001 1.50 (1.34–1.69)
Baseline age (yr) 19–24 0.39 (0.22–0.69) 0.001 0.53 (0.30–0.94) 0.031 0.52 (0.29–0.93)
25–34 0.63 (0.55–0.73) <0.001 0.71 (0.61–0.82) <0.001 0.70 (0.60–0.81)
35–44 Referent Referent Referent
45–54 1.49 (1.30–1.70) <0.001 1.37 (1.20–1.57) <0.001 1.36 (1.19–1.56)
55 1.89 (1.50–2.37) <0.001 1.69 (1.34–2.13) <0.001 1.61 (1.28–2.03)
Sex Male 1.40 (1.25–1.56) <0.001 1.48 (1.31–1.67) <0.001 1.47 (1.30–1.66)
Female Referent Referent Referent
Baseline body mass
index (kg/m2)
10–17
18–24
0.40 (0.23–0.71)
0.65 (0.53–0.81)
0.004
0.001
0.35 (0.19–0.63)
0.61 (0.48–0.76)
0.002
0.001
0.35 (0.19–0.62)
0.61 (0.48–0.76)
25–34 Referent Referent Referent
35þ 1.44 (1.14–1.82) 0.004 1.57 (1.24–1.98) <0.001 1.58 (1.25–1.99)
Excluded by AIC
Baseline CD4 count
(cells/ml)
0–199
200–349
1.06 (0.93–1.21)
Referent
0.415 1.11 (0.97–1.27)
Referent
0.136
350þ 1.32 (1.11–1.57) 0.001 1.11 (0.91–1.36) 0.307
Baseline viral load
(copies/ml)
0–999
1000–99,999
1.35 (1.17–1.57)
Referent
<0.001 1.27 (1.06–1.53)
Referent
0.010 1.27 (1.09–1.48)
Referent
100,000–999,999 1.03 (0.90–1.18) 0.653 0.99 (0.86–1.13) 0.841 1.00 (0.87–1.14)
1,000,000 1.15 (0.88–1.50) 0.311 1.15 (0.88–1.50) 0.320 1.15 (0.88–1.50)
haz
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